Rapport Therapeutics (RAPP) Accounts Payables (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Accounts Payables data on file, last reported at $6.6 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 206.73% year-over-year to $6.6 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a 206.73% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 114.43% from the prior year.
• Accounts Payables for Q1 2026 stood at $6.6 million, up from $4.2 million in the prior quarter.
• Over the last five years, Accounts Payables for RAPP reached as high as $6.6 million in Q1 2026 and fell as low as $1.3 million in Q3 2024.
• Historically, Accounts Payables has averaged $3.0 million across 4 years, with a median of $2.5 million in 2023.
• Across the five-year window, Accounts Payables fell 21.9% in 2024 and soared 206.73% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $2.5 million in 2023, then retreated by 21.9% to $2.0 million in 2024, then surged by 114.43% to $4.2 million in 2025, then soared by 56.59% to $6.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $6.6 million in Q1 2026, $4.2 million in Q4 2025, and $3.2 million in Q3 2025.